In summary, our data indicated that DLG5 expression was down‐regulated in ER+ TAM‐resistant breast cancer tissues and cells, and DLG5 silencing increased the resistance to TAM and breast cancer cell stemness by enhancing TAZ expression and nuclear translocation in ER+ breast cancer cells. Here, DLG5 is linked to breast carcinoma.